TOPICS

Category: Rosacea

Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions

J Clin Aesthet Dermatol. 2021;14(3):E53–E57.  by Terry M. Jones, MD, and Iain Stuart, PhD Dr. Jones is with J&S Studies Inc., in College Station, Texas. Dr. Stuart is with VYNE Therapeutics Inc., in Bridgewater, New Jersey.  FUNDING: This study was sponsored by Foamix Pharmaceuticals Ltd., a wholly owned subsidiary of VYNE Therapeutics Inc. DISCLOSURES: Dr.

CONTINUE READING »

Severe Granulomatous Rosacea with Cutaneous Lupus Erythematosus

J Clin Aesthet Dermatol. 2021;14(2):22–24. by Rym Afiouni, MD; Josiane Helou, MD; Stephanie Matar, MD; and Roland Tomb, MD, PhD All authors are with the Department of Dermatology, Hôtel-Dieu de France University Hospital, Saint Joseph University in Beirut, Lebanon. FUNDING: No funding was provided for this article. DISCLOSURES: The authors report no conflicts of interest

CONTINUE READING »

Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

J Clin Aesthet Dermatol. 2020;13(11):44–49 by Linda Stein Gold, MD; James Q. Del Rosso, DO; Leon Kircik, MD; Neal D. Bhatia, MD; Deirdre Hooper, MD; Walter Nahm, MD, PhD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Del Rosso is the Research Director at JDR

CONTINUE READING »

Selected Poster Abstracts from MauiDerm for Dermatologists 2020

A message from the Guest Editor and MauiDerm Program Director, George Martin, MD Dear Colleagues: The 2020 edition of the MauiDerm for Dermatologists meeting had a variety of clinical and scientific data presented, but not just at the podium. A wide range of clinically relevant material was also presented in poster format. For those of

CONTINUE READING »